Ness Ziona, Israel

Michael Fassler

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Michael Fassler: Innovator in Antibody Research

Introduction

Michael Fassler is a prominent inventor based in Ness Ziona, IL. He has made significant contributions to the field of antibody research, holding a total of four patents. His work focuses on developing antibodies that have the potential to impact medical diagnostics and treatments.

Latest Patents

Fassler's latest patents include groundbreaking innovations such as "Transthyretin antibodies and uses thereof." This patent provides antibodies and antigen-binding fragments that specifically bind to human transthyretin (TTR). These anti-TTR antibodies are useful for detecting TTR and treating TTR amyloidosis in subjects. Another notable patent is "TREM2 antibodies and uses thereof," which offers antibodies that specifically bind to human Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). These anti-TREM2 antibodies are valuable for detecting TREM2 and treating neurodegenerative diseases.

Career Highlights

Fassler is associated with Mor Research Applications Ltd., where he continues to advance his research in antibody development. His work has garnered attention for its potential applications in treating serious health conditions.

Collaborations

Fassler collaborates with Jacob George, contributing to the innovative environment at Mor Research Applications Ltd. Their partnership enhances the research capabilities and fosters the development of new therapeutic solutions.

Conclusion

Michael Fassler's contributions to antibody research exemplify the impact of innovation in the medical field. His patents reflect a commitment to advancing healthcare through scientific discovery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…